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Influenza is an important disease in children. In April 2009, human infections caused 
by a novel swine H1N1 virus were reported in Mexico, followed by a pandemic. As 
of 14 March 2010, more than 213 countries and overseas territories or communities 
have reported laboratory-confirmed cases of pandemic influenza H1N1 2009, 
including at least 16,813 deaths. This influenza pandemic is unique in many 
respects. Large outbreaks occurred outside the usual season for influenza infec-
tion. The virus also caused severe illnesses and deaths in younger people, with 
many deaths caused by severe pneumonia. A comprehensive approach to pandemic 
control has been launched, including infection control interventions, antiviral drugs 
and vaccines. Vaccination is the most efficient way to control morbidity and mor-
tality resulting from influenza infections in humans. For the first time, an influenza 
vaccine against a pandemic strain became available before the winter. However, 
the initially smooth influenza vaccination program was disturbed by the fear of 
possible adverse events following immunization. In Taiwan, mistrust of the influ-
enza vaccination has also caused significant social impacts towards the end of 2009. 
Lessons learned from this pandemic influenza H1N1 2009 might help health autho-
rities and physicians shape their preparedness for the next pandemic.
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1.  Pandemic (H1N1) 2009 Influenza
In March and early April 2009, a new swine-origin 
influenza A (H1N1) virus emerged in Mexico and the 
United States (US), characterized by a unique com-
bination of gene segments that had not been iden-
tified among human or swine influenza A viruses.1 
On 11 June 2009, the World Health Organization 
(WHO) declared pandemic phase 6, and the world 
moved into the first influenza pandemic of the 21st 
century. As of March 14th, 2010, more than 213 coun-
tries and overseas territories or communities had 
reported laboratory-confirmed cases of pandemic 
influenza H1N1 2009, including at least 16,813 deaths.2 
The pandemic (H1N1) 2009 is unique in many re-
spects. It had taken less than 6 weeks since the 
first notification to the WHO of the new H1N1 in-
fections in humans and the subsequent spread of 
the virus throughout the world. In contrast, past 
pandemics have taken about six months to become 
established; this is probably a reflection of our in-
creasing global mobility.3 Large outbreaks occurred 
outside the usual season for influenza. The virus 
also caused severe illness and deaths in younger 
people, with many deaths caused by severe pneu-
monia. Table 14 illustrates the major events that 
happened during the 2009 H1N1 influenza pandemic 
in Taiwan.
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2.  Influenza Pandemics in History
The influenza virus derived its name in the 14th−
15th Century when a Florentine family used the word 
“influence” to suggest an unusual conjunction of 
planets at times of cough, cold or fever epidemics. 
The word “influenza” was thus derived as a des-
cription for the epidemics due to “influences” or 
“ab occulta coeli influential”.5 Our world has been 
affected by influenza epidemics and pandemics for 
many centuries. The three previous influenza pan-
demics in the 20th century, A/H1N1 from 1918 to 
1919 (“Spanish flu”), A/H2N2 from 1957 to 1963 
(“Asian flu”), and A/H3N2 from 1968 to 1970 (“Hong 
Kong flu”), were characterized by a shift in the 
virus subtype, a shift of the highest mortality to 
younger populations, successive pandemic waves, 
higher transmissibility than seasonal influenza, 
and different impacts in different geographic re-
gions.6 In 1918, the influenza epidemic also swept 
through all 12 administrative districts of Taiwan in 
less than a month. The total estimated number of 
excess deaths was 51,048. Given the average Taiwan 
population size during 1918−1920, the percentage 
of excess deaths was about 1.38%.7
3.  Discovery and Biological 
Characteristics of Influenza A Virus
The influenza virus was for the first time isolated 
from human in 1933 by Smith, Andrews and Laidlaw.8 
Influenza viruses are members of the family Ortho-
myxoviridae and include influenza virus types A, B 
and C. The genome of influenza A viruses consists 
of 8 single-stranded RNA segments encoding 11 
proteins, including two major glycoproteins, hemag-
glutinin and neuraminidase, on its surface. Stan-
dard influenza nomenclature includes the virus type 
(A, B, or C), geographical origin, strain number, year 
of isolation, and virus subtype. Thus, the pandemic 
(H1N1) 2009 influenza virus isolated in California 
in 2009 is identified as influenza A/California/04/
2009 (H1N1). Influenza A subtype classification is 
based on the antigenicity of hemagglutinin and neu-
raminidase. With at least 16 different hemaggluti-
nin and 9 different neuraminidase subtypes, there is 
considerable antigenic variation among influenza 
viruses. Widely circulating human influenza viruses 
seem to have been limited to three hemagglutinin 
(H1, H2 and H3) and two neuraminidase (N1 and N2) 
subtypes; birds are the predominant hosts for the 
Table 1 Major events during the influenza A (H1N1) 2009 pandemic in Taiwan4
Apr 28 CECC held its first meeting in response to WHO influenza pandemic alert phase 4
 Novel influenza A/H1N1 listed as Category I Notifiable Infectious Disease
May 20 CECC confirmed first imported case of influenza A (H1N1)
May 25 CECC confirmed first domestic case of influenza A (H1N1)
Jun 11  WHO raised the level of influenza pandemic alert to phase 6 and declared a pandemic of moderate 
severity
Jun 19  Influenza A (H1N1) removed from the list of Category I Notifiable Infectious Diseases and included in 
the list of Category IV Notifiable Infectious Diseases
Jul 17 CECC announced the first severe case of pandemic influenza A (H1N1)
Jul 30 First death from pandemic influenza A (H1N1)
Aug 15  First pediatric death from pandemic influenza A (H1N1)
The first severe case of pandemic influenza A (H1N1) in a pregnant woman
Aug 17 A cluster outbreak at a military base located in central Taiwan
Aug 18 CECC presented the “325”* school closure recommendations and guidelines
Aug 26  Advisory Committee on Immunization Practices announced pandemic influenza A (H1N1) vaccine 
priority list
Oct 1 2009 seasonal influenza vaccine available in Taiwan
Oct 20 Discovery of the first Oseltamivir-resistant pandemic influenza A (H1N1) virus strain in Taiwan
Nov 1 People affected by Typhoon Morakot received first batch of influenza A (H1N1) vaccine
Nov 5 Influenza A (H1N1) infection in pigs on a pig farm in Taitung
Nov 16 Mass immunization campaign against pandemic (H1N1) at elementary schools began
Nov 23 Immunization of junior high school students began
Nov 30 Immunization of senior high school students began
Dec 12 Nationwide H1N1 vaccination campaign began
*325 means that “within 3 days, when 2 or more students in the same class are diagnosed to have contracted influenza, a class is 
suspended for 5 days, including weekends and holidays”. CECC = Central Epidemic Command Center.
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other subtype strains. As a result of changes in the 
surface glycoproteins of the virus, de vastating epi-
demics and pandemics have occurred in humans; 
in addition, major epizootics have been reported 
in poultry, pigs, horses, seals and camels.9
4.  Laboratory Diagnosis for Pandemic 
(H1N1) 2009 Influenza Virus
A confirmed case of pandemic (H1N1) 2009 influ-
enza virus infection is defined as an individual with 
laboratory-confirmed (H1N1) 2009 influenza virus 
infection by one or more of the following tests: 
real-time reverse transcriptase-polymerase chain 
reaction (RT-PCR), viral culture or four-fold rise in 
(H1N1) 2009 influenza virus-specific neutralizing 
antibodies.10 Viral culture and RT-PCR can reliably 
identify the presence of (H1N1) 2009 influenza virus 
in specimens, especially with RT-PCR, which has the 
highest sensitivity and specificity. With RT-PCR, 
(H1N1) 2009 influenza virus will test positive for 
influenza A and negative for seasonal H1 or H3. 
Strong reactivity for influenza A (cycle threshold 
value < 30) is indicative of 2009 H1N1. Commercially 
available rapid influenza diagnostic tests (RIDTs) 
detect influenza viral nucleoprotein antigen, and 
is capable of providing results within 30 minutes. 
The sensitivity of RIDTs for detecting (H1N1) 2009 
influenza has varied from 10% to 70%, and is directly 
related to the amount of virus in the specimen but 
inversely related to the threshold cycle value of 
the test.11 Rapid screening tests for influenza may 
detect the presence of antigen from either influ-
enza A or influenza B in respiratory specimens. 
Although rapid screening tests have a high specifi-
city (> 95%), their sensitivities are variable when 
compared with RT-PCR. A negative result from a 
screening test does not rule out influenza virus 
infection.12 Screening tests cannot distinguish 
H1N1 novel influenza from seasonal H1N1 or H3N2 
influenza A viruses.
5.  Treatment of Influenza Infection
The neuraminidase enzyme is responsible for cleav-
ing sialic acid residues on newly formed virions; 
this is essential for the release of recently formed 
viral particles from the infected cell. Thus, the en-
zyme helps with the spread of the virus to other cells. 
Neuraminidase inhibitors block the enzyme’s abil-
ity to cleave sialic acid residues on the surface of 
the infected cell, thereby inhibiting the release of 
progeny virions from the infected cells and reducing 
infectivity.13 To date, with few exceptions, the 2009 
H1N1 virus remains susceptible to neuraminidase 
inhibitors (oseltamivir and zanamivir) and resistant 
to the adamantanes (amantadine and rimantadine).14 
Antiviral treatment is recommended for all hospi-
talized patients with confirmed, probable, or sus-
pected 2009 H1N1 infection and those at high risk 
for complications.15 The first oseltamivir-resistant 
pandemic influenza A (H1N1) virus strain in Taiwan 
was isolated from a 20-year-old male in October, 
2009.16 The virus isolated from the case prior to 
oseltamivir treatment was sensitive to oseltamivir. 
However, the virus isolated three days after initia-
tion of treatment displayed a mutation involving 
the substitution of a histidine for tyrosine at posi-
tion 275 (H275Y), which was resistant to oseltami-
vir, de monstrating mutation of the virus after the 
treatment administration.16 Oseltamivir treatment 
was not associated with statistically significant re-
duction in the duration of viral shedding,17 thereby 
proving ineffective in preventing viral spread in 
community.
6.  Influenza Vaccines
Vaccination is the most effective measure for pre-
venting influenza-associated morbidity and mor-
tality. The first experiments on the attempted 
immu nization of animals were made in the US by 
Francis and Magill in 193518 and in England by Andrews 
and Smith in 1937.19 In the 1940s, the virus could be 
propagated in embryonated hen’s eggs by research-
ers. The first vaccines against influenza were 
formaldehyde-inactivated whole-virus vaccines. They 
were developed by the US armed services and made 
commercially available in 1945 in the US. However, 
early influenza vaccines were relatively crude prep-
arations of chick embryo allantoic fluid virus; they 
were frequently contaminated with bacterial en-
dotoxin, which would evoke febrile reactions after 
vaccination and were contraindicated in children. 
Purification of virus from infected chicken em-
bryos using zonal ultracentrifugation has become 
the manufacturing process of choice for most mar-
keted influenza vaccines for years and is still used 
currently.20 Today, licensed influenza vaccines are 
tripartite, aiming to protect against two influenza 
A strains and one influenza B, as guided by the WHO. 
They exist in various forms, inactivated whole virus, 
split virus, subunit, or cold-adapted live virus vac-
cine (Table 218,21−28). These seasonal vaccines have 
a protective efficacy in the range of 60−90%.29 The 
vaccine industry also started working with other 
new modalities recently, including new adjuvant, 
reverse genetics techniques, recombinant DNA, 
vector-based vaccines, synthetic peptide vaccines 
and universal influenza vaccines targeting common 
epitopes.30 Although the influenza vaccine had been 
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used for 60 years, it never worked in pandemics until 
2009. For the first time, a vaccine against a pan-
demic strain of influenza became available before 
the on set of winter, a time when lower temperatures 
and humidity allow the virus to spread more easily.
7.  Pandemic Influenza A (H1N1) 2009 
Vaccination in Taiwan
Taiwan has been implementing its annual seasonal 
influenza vaccination program for over a decade. 
In response to the pandemic, the new influenza A 
(H1N1) vaccine has been included in the program 
since November 1st, 2009, along with the routine 
seasonal influenza vaccines. However, due to the 
limited supplies of influenza vaccine, Taiwan’s Ad-
visory Committee on Immunization Practices an-
nounced a pandemic influenza A (H1N1) vaccine 
priority list in late August of 2009. The top-listed 
groups included homeless people affected by 
Typhoon Morakot, health care and public health per-
sonnel, pregnant women, preschool children aged 
between 1 through 6 years, people with major ill-
ness/injury (aged 7 years and older), elementary 
school students (aged 7 through 12 years) and junior 
high school students (aged 13 through 15 years).31 
The pandemic H1N1 vaccination campaign in 
Taiwan used two types of vaccine: AdimFlu-S (un-
adjuvanted H1N1v; Adimmune, Taichung, Taiwan) 
and Focetria (MF59 adjuvanted H1N1v; Novartis 
International AG, Basel, Switzerland). As of March 2nd, 
2010, 5.12 million and 0.53 million doses of AdimFlu-S 
and Focetria had been administrated, respectively.
8.  Debate on Pandemic Influenza A 
(H1N1) 2009 Vaccine in Taiwan
The massive vaccination program for pandemic in-
fluenza A (H1N1) 2009 in Taiwan was disturbed by 
an unfounded public fear about possible adverse 
events following immunization. Theoretically, the 
safety profile of such an emergent pandemic vaccine 
will likely be less certain than that of previously 
released influenza vaccines. As such, the safety of 
this vaccine will need to be closely monitored. Ac-
cording to the database of the Taiwan Centers for 
Disease Control, 1,381 suspected adverse events 
were reported by the “hotline 1922” in more than 
5.6 million immunizations between November 4th, 
2009 and March 19th, 2010.32 The Vaccine Injury 
Compensation Program (VICP) has received a total 
of 390 claims requesting compensation for individ-
uals thought to be injured by the pandemic influ-
enza A (H1N1) vaccine. Until now, none of those 
death/life-threatening events could be directly at-
tributed to H1N1 vaccine after being reviewed by 
the Vaccine Injury Compensation Program (VICP) 
of Department of Health Taiwan. The overall rate 
of adverse events seemed comparable with those 
for the seasonal influenza vaccines used for years 
in Taiwan. Randomized control trials on pandemic 
influenza A (H1N1) 2009 vaccines in Australia and 
the United States also led to the conclusions that 
safety and reactogenicity of the vaccine were ac-
ceptable and similar to those of seasonal vac-
cines.33,34 However, mistrust of the influenza vaccine 
reached a historic high at the end of 2009. The 
Gallup Market Research Corp conducted an H1N1 
Table 2 Milestones in influenza vaccine development18,21−28
Year Influenza A strain(s) Viability Remark Reference
1935 A/Puerto Rico/8/34 Inactivated First trials with killed virus from 18
 (H1N1) (PR8)  mouse lungs
1945 A/PR/8/34 Inactivated First whole-virus vaccines from 21
 (H1N1)-like  embryonated eggs
1950 A/PR/8/34 (H1N1) Inactivated First mineral oil-adjuvanted 22
   whole virus vaccines
1967 A/PR/8/34 (H1N1) Inactivated First aluminum phosphate 23
 A/Taiwan/4/64 (H2N2)  adjuvanted whole-virus vaccines
 A/Ann Arbor/1/57 (H1N1)
1968 A/Japan/170/62 (H2N2) Inactivated First split-virus vaccines 24
1976 A/England/42/72 (H3N2) Inactivated First subunit vaccines 25
1997 A/Wuhan/359/95 (H3N2) Inactivated First MF59 adjuvanted 26
 A/Bayern/7/95 (H1N1)  subunit vaccines
2004 A/New Caledonia/20/99 (H1N1) Live-attenuated Intranasal cold-adapted live vaccines 27
2007  A/Solomon Islands/3/2006 (H1N1) Inactivated First cell-culture subunit vaccines 28
A/Wisconsin/67/2005 (H3N2)
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awareness survey between January 5th and January 
6th, 2010 and an H1N1 vaccination survey for people 
aged 18 and above between January 7 and January 
9, 2010. Approximately 40% of people in Taiwan in-
dicated that they had decided against vaccination 
because of recent reports concerning vaccine ad-
verse events.35 Meanwhile, celebrities around the 
world were denouncing it, proudly proclaiming that 
they would not give it to their H1N1-vulnerable chil-
dren, and many others followed their advice. The 
Internet has also fueled rumors about the vaccine, 
ranging from the simply false (“It hasn’t been tested 
on humans”) to the paranoid (“It’s a WHO-led plot 
to depopulate the world”).36 The Internet plays a 
large role in disseminating anti-vaccination infor-
mation. Anti-vaccination protestors make postmod-
ern arguments that reject biomedical and scientific 
facts in favor of their own interpretations. Pro-
vaccination advocates who focus on correcting mis-
information reduce the controversy to merely an 
educational problem; however, these postmodern 
discourses must be acknowledged in order to begin 
a dialogue.37 The first suspected vaccine-related 
death in children has also been proved to be caused 
by parvovirus B19 infection. The H1N1 vaccination 
coverage rate is the highest among students from 
first through third grade who have received the first 
of the two H1N1 vaccine doses (86.1%), followed 
by healthcare personnel (82%) and students from 
fourth through sixth grade (76.6%).35 The overall 
coverage rate is around 70% in high school students. 
The numbers of school closures, and outpatient and 
emergency room visits for influenza-like illness de-
clined after the implementation of H1N1 vaccina-
tion in high school students.38,39
9.  Social Impacts After Vaccination
The most common adverse effects of novel swine 
influenza vaccinations in children were pain or swell-
ing at the injection site, fever and irritability.33,34 
Many reported adverse events following the immu-
nization of the pandemic influenza A (H1N1) 2009 
vaccine in Taiwan during the vaccination campaign 
have been proved irrelevant to vaccines but psy-
chogenic in nature. DSM-IV subsumes this condition 
under the rubric of “Somatoform disorders” and 
within the subcategory “Conversion disorder”.40 
When vaccines are administered to groups, the 
physical reactions of the recipients may be similar, 
causing a form of mass reaction, the mechanism for 
which is the same as that for mass reactions from 
other causes. These phenomena have been catego-
rized as “mass sociogenic illness”,41 and have been 
defined as the collective occurrence of a constella-
tion of symptoms suggestive of organic illness, but 
without an identified cause in a group of people with 
shared beliefs about the cause of the symptoms.42
10.  Where Are We Going?
On the basis of the historical interpretations of the 
waves of impact during the 1918 pandemic, some 
have speculated that this current 2009 H1N1 virus 
has the potential to become more virulent.43 The 
current pandemic has killed 41 Taiwanese and made 
908 people seriously ill between April, 2009 and 
February, 2010. The government has spent approx-
imately NT$3 billion on buying 15 million vaccine 
doses and on running the 3,000 clinics for vaccina-
tion administration to the public. A total of 5.64 
million vaccine doses were used to immunize 25 
percent of the population among which 75 percent 
were aged under 18.44 Moreover, the recent deci-
sion by the WHO to include the pandemic influenza 
A (H1N1) virus in the composition of the 2010 north-
ern hemisphere influenza vaccine and its calling of 
an expert meeting on February 23rd, 2010 signaled 
that the peak of the H1N1 pandemic had come to a 
close.45 Further, according to the surveillance data 
collected by the Taiwan Centers for Disease Control, 
no new local outbreak of H1N1 infection occurred 
during the Chinese New Year holiday, demonstrat-
ing that the implementation of relevant disease 
control policies has effectively stopped the spread 
of the virus.
11.  Conclusions
For the past nearly 40 years, scientists have been 
warning that an influenza pandemic on the order of 
the 1918 Spanish flu could strike at any moment. 
They imagined the perpetrator would emerge in 
Asia, and worried that the avian influenza strain 
H5N1 might be it. However, the pandemic in 2009 
looks nothing like previous speculations. Not only 
did it begin in North America, but the swine virus 
behind it was a novel form of an H1N1 strain al-
ready circulating in humans. Although the new H1N1 
virus is unusually dangerous for the young and for 
pregnant women, it causes a disease not more se-
vere than seasonal influenza in most otherwise 
healthy people. Will the next pandemic be as mild 
as the recent one? Nobody knows. Vaccination is still 
the most effective way to block pandemic influenza, 
according to the domestic epidemiological surveil-
lance data. It might not be a matter of “whether” 
but “when” the next pandemic comes. Therefore, 
the global community must recognize the econo-
mic, security, and health threats posed by the next 
influenza pandemic and invest accordingly. Health 
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authorities and researchers should also check their 
preparedness according to the lessons learned 
from the 2009 pandemic.
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